108 related articles for article (PubMed ID: 35321552)
21. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
22. New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.
Chu K; Corcoran N; Norden S; Wong LM
Anticancer Agents Med Chem; 2018; 18(7):951-957. PubMed ID: 29141559
[TBL] [Abstract][Full Text] [Related]
23. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
[TBL] [Abstract][Full Text] [Related]
24. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.
Bishoff JT; Freedland SJ; Gerber L; Tennstedt P; Reid J; Welbourn W; Graefen M; Sangale Z; Tikishvili E; Park J; Younus A; Gutin A; Lanchbury JS; Sauter G; Brawer M; Stone S; Schlomm T
J Urol; 2014 Aug; 192(2):409-14. PubMed ID: 24508632
[TBL] [Abstract][Full Text] [Related]
25. Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer.
Li X; Wan X; Chen H; Yang S; Liu Y; Mo W; Meng D; Du W; Huang Y; Wu H; Wang J; Li T; Li Y
Clin Cancer Res; 2014 May; 20(9):2312-25. PubMed ID: 24610824
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
[TBL] [Abstract][Full Text] [Related]
27. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
28. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
[TBL] [Abstract][Full Text] [Related]
29. Unbiased data mining identifies cell cycle transcripts that predict non-indolent Gleason score 7 prostate cancer.
Johnston WL; Catton CN; Swallow CJ
BMC Urol; 2019 Jan; 19(1):4. PubMed ID: 30616540
[TBL] [Abstract][Full Text] [Related]
30. Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score.
Renard-Penna R; Cancel-Tassin G; Comperat E; Varinot J; Léon P; Roupret M; Mozer P; Vaessen C; Lucidarme O; Bitker MO; Cussenot O
J Urol; 2015 Dec; 194(6):1617-23. PubMed ID: 26272031
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
[TBL] [Abstract][Full Text] [Related]
32. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
33. Development of a predictive model for stromal content in prostate cancer samples to improve signature performance.
Boufaied N; Takhar M; Nash C; Erho N; Bismar TA; Davicioni E; Thomson AA
J Pathol; 2019 Dec; 249(4):411-424. PubMed ID: 31206668
[TBL] [Abstract][Full Text] [Related]
34. Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue.
Medlow PW; Steele CJ; McCavigan AM; Reardon W; Brown CM; Lambe SM; Ishiy FAA; Walker SM; Logan GE; Raji OY; Berge V; Katz B; Kay EW; Sheehan K; Watson RW; Harkin DP; Kennedy RD; Knight LA
BMC Med Genomics; 2018 Dec; 11(1):125. PubMed ID: 30591067
[TBL] [Abstract][Full Text] [Related]
35. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of a 32-gene prognostic index for prostate cancer progression.
Wu CL; Schroeder BE; Ma XJ; Cutie CJ; Wu S; Salunga R; Zhang Y; Kattan MW; Schnabel CA; Erlander MG; McDougal WS
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6121-6. PubMed ID: 23533275
[TBL] [Abstract][Full Text] [Related]
37. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
38. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
39. An accurate prostate cancer prognosticator using a seven-gene signature plus Gleason score and taking cell type heterogeneity into account.
Chen X; Xu S; McClelland M; Rahmatpanah F; Sawyers A; Jia Z; Mercola D
PLoS One; 2012; 7(9):e45178. PubMed ID: 23028830
[TBL] [Abstract][Full Text] [Related]
40. Long noncoding RNA SNHG7 accelerates prostate cancer proliferation and cycle progression through cyclin D1 by sponging miR-503.
Qi H; Wen B; Wu Q; Cheng W; Lou J; Wei J; Huang J; Yao X; Weng G
Biomed Pharmacother; 2018 Jun; 102():326-332. PubMed ID: 29571017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
